A fatal hypotension by sildenafil in an end-stage renal disease patient with hypertension and abnormal pharmacokinetics of the medicine.

摘要

A FATAL HYPOTENSION BY SILDENAFIL IN AN END-STAGE RENAL DISEASE PATIENT WITH HYPERTENSION AND ABNORMAL PHARMACOKINETICS OF THE MEDICINE Sildenafil (Viagra~R, Pfizer, Japan) is a potent therapeutic medicine for erectile dysfunction (ED), but its potential vasodilator activity may cause blood pressure (BP)-lowering as a side effect. The maximum plasma concentration (Cmax) values of sildenafil in elderly patients or patients with severe renal impairment were 70-80% higher in comparison with patients without these factors, which suggests a high risk of its hypotensive side effect in elderly patients with end-stage renal disease (ESRD).